DENTSPLY SIRONA Inc.
XRAY · Price history
Price at last available close
$9.35
+$0.07 (+0.75%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About DENTSPLY SIRONA Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering.
How they make money
Dentsply Sirona generates revenue by developing, manufacturing, and marketing a comprehensive portfolio of professional dental products, equipment, and cloud-enabled software solutions. The company sells these products primarily through a global network of dental distributors and directly to dental practices, laboratories, and healthcare institutions, earning income through product sales and associated service and maintenance contracts.
Products & services
Comprehensive dental solutions including digital imaging systems, treatment centers, CAD/CAM systems, dental implants, orthodontic products, restorative materials, and urology/enterology consumables.
Brands & revenue mix
Flagship brand for digital dental equipment and imaging.
Separate brand revenue is not available in this research.Source
Core brand for dental consumables and restorative products.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
The company relies heavily on a network of independent dental distributors to reach end-users, noting that the loss of key distribution partners could materially impact results as of the period ending 2025-12-31.
Suppliers, materials & equipment
- Contract Manufacturers — The company utilizes various third-party contract manufacturers for the production of certain components and finished goods; specific supplier names are not disclosed.Source
Competitors
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
23
Poor
Financial Strength
47
Business Quality / Moat
3
Management
18
Growth Quality
20
Risk / Durability
21
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
34
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
41/100
Building Historical Record
Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for XRAY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving XRAY's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is XRAY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is XRAY's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for XRAY to reach sustainable profitability?
- •What future growth or profitability would be needed to justify XRAY's current valuation?
Essential Investment Snapshot
Wall Street Score
22
Opportunity Score
34
Market Cap
$1.86B
P/E Ratio
-3.2
EPS
$-2.74
52-Week High
$14.76
52-Week Low
$8.61
Beta
0.85
Analyst Target
$14.00
Shares Outstanding
199.4M
Total Revenue
$3.64B
Total Debt
$2.31B
Dividend Yield (TTM)
1.71%
Liquidation Value / Share
$6.78
Dividend / Share (TTM)
$0.16
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for XRAY
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Community Sentiment
0 active · 0 total callsNo personal call yet on XRAY.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Extensive global distribution network.
- +Broad portfolio of dental technologies and consumables.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −Dependence on third-party distributors.
- −Intense competition and pricing pressure.
- −Regulatory compliance and product liability risks.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
21
Jul 24, 2026
Change
+1.2
points
Current Score
22
Oct 1, 2026
Category Changes
XRAY increased 1.2 points because Revenue improved by 5.7 points, Asset improved by 6.2 points, Buffett improved by 2.1 points.
Positive Contributors
- + Revenue improved by 5.7 points
- + Asset improved by 6.2 points
- + Buffett improved by 2.1 points
Projected Score
Projected Score
22
Projected Change
-0.2 points
Preliminary comparable-period financial changes suggest decline of approximately 0.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$9.35
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.64B | $3.68B | $3.79B | $3.96B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.84B | $1.84B | $1.83B | $1.88B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.80B | $1.84B | $1.96B | $2.09B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $166.0M | $150.0M | $165.0M | $184.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.46B | $1.44B | $1.60B | $1.61B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.38B | $1.59B | $2.84B | $2.17B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $172.0M | -$46.0M | -$518.0M | $249.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $426.0M | $252.0M | -$879.0M | -$85.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $91.0M | $88.0M | $69.0M | $81.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$347.0M | -$486.0M | -$936.0M | -$175.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $200.0M | $112.0M | -$26.0M | -$43.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$546.0M | -$598.0M | -$910.0M | -$132.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.74 | $-3.00 | $-4.48 | $-0.62 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 200M | 199M | 203M | 212M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 201M | 199M | 203M | 212M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$898.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.18
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-7.3%
Cash Change
-33.4%
Margin Change
+8.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included debt levels, net income margin. Pressure indicators included revenue growth, EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 4.1%. EPS declined 178.3%. Cash declined 33.4%. Total debt declined 7.3%. Net income margin improved by 8.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio
DENTSPLY SIRONA (NASDAQ:XRAY) Reaches New 1-Year Low – Time to Sell?
Engineers Gate Manager LP Boosts Stake in DENTSPLY SIRONA Inc. $XRAY
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now
Rumor Mill · XRAY
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial